A major transition in malaria treatment: The adoption and deployment of artemisinin-based combination therapies
A major transition in malaria treatment: The adoption and deployment of artemisinin-based combination therapies
复制标题
DOI：
10.4269/ajtmh.2007.77.193
复制
发表时间：
2007-12-01
影响因子：
3.3
通讯作者：
Mendis, Kamini N.
中科院分区：
文献类型：
--
作者：
Bosman, Andrea;Mendis, Kamini N.
近年来，寄生虫对传统抗疟药物的耐药性导致疟疾治疗发生了巨大转变。 67 个恶性疟原虫疟疾流行的国家（其中 41 个在非洲）最近采用了高效的青蒿素联合疗法 (ACTS)。 2005年，全球采购了3130万个ACT疗程供公共部门使用，其中2550万个在非洲。然而，在部署 ACTS 的 39 个国家，特别是 21 个非洲国家，获得这些药物的机会仍然低得令人无法接受。经过一段时间的市场不稳定，目前ACTS的全球制造能力足以满足需求。然而，为了扩大目前的 ACT 覆盖范围，需要增加和持续的融资。青蒿素作为单一疗法在 47 个流行国家的私营部门广泛使用，如果其消费不减，将促进对青蒿素的耐药性并损害 ACT 的有效性。
Parasite resistance to conventional antimalarial medicines has led, in recent years, to a dramatic shift in malaria treatment. Sixty-seven countries with endemic Plasmodium falciparum malaria, 41 of them in Africa, have recently adopted the highly effective artemisinin-based combination therapies (ACTS). In 2005, 31.3 million ACT treatment courses were procured globally for public sector use, 25.5 million of them in Africa. However, in the 39 countries, and in particular the 21 African countries in which ACTS are being deployed, access to these medicines is still unacceptably low. After a period of market instability, the global manufacturing capacity for ACTS is now sufficient to meet the demand. However, increased and sustained financing will be necessary to extend the current levels of ACT coverage. Artemisinins as monotherapies are widely available in the private sector of 47 endemic countries, and their consumption will, if unabated, promote resistance to artemisinins and compromise the effectiveness of ACTs.